Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
National Institutes of Health · Department of Health and Human Services
At a glance
Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed) is an open federal cooperative agreement opportunity from the National Institutes of Health (Department of Health and Human Services). Applications are due September 10, 2027. Applicant types listed as eligible include state governments, county governments, city or township governments, special district governments, independent school districts and 10 more. Cost sharing is not required. It is funded under Assistance Listing 93.393 (Cancer Cause and Prevention Research).
Summary assembled from the official notice's fields. The official notice governs.
Key facts
- Dec 13, 2024Posted
- Sep 10, 2027Application deadlinenext date
- Oct 16, 2027Archived
- Posted
- Dec 13, 2024
- Close date
- Sep 10, 2027
- Archive date
- Oct 16, 2027
- Award floor
- Not specified
- Award ceiling
- Not specified
- Est. total funding
- Not specified
- Expected awards
- Not specified
- Cost sharing
- Not required
- Funding instrument
- Cooperative Agreement
- Opportunity category
- Discretionary
Typical awards for this program (SAM.gov listing for ALN 93.393, not this notice): Range: $927 to $3,046,580 Average: $568,686
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public colleges & universities
- Federally recognized tribal governments
- Public & Indian housing authorities
- Native American tribal organizations
- 501(c)(3) nonprofits
- Nonprofits without 501(c)(3) status
- Private colleges & universities
- For-profit organizations (not small businesses)
- Small businesses
- Others (see notice)
Additional information on eligibility (from the notice)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
A quick check against the listed applicant types — other requirements in the notice still apply.
Based on the published notice. Review the official notice for complete eligibility requirements.
What it funds
Official synopsis as published by the agency, formatted for readability.
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as liquid biopsies", or other biospecimens as described in this NOFO. Extramural research funded under this NOFO may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for "liquid biopsies", tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.
Full announcement & documents
The full announcement has the complete rules — page limits, required attachments, evaluation criteria and any letter-of-intent dates. Files download directly from Grants.gov.
How to apply
0 of 8 done · progress saved in this browser
Assistance Listing
What is an ALN?Reported obligations under ALN 93.393
Historical data · not a predictionAgency contact (as published)
National Institutes of Health
grantsinfo@nih.gov
301-402-2541
Quick answers
When is the deadline for this opportunity?
According to the official notice, applications are due September 10, 2027. Confirm the deadline and submission time on Grants.gov before applying.
Who is eligible to apply for this opportunity?
The official notice lists these applicant types as eligible: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public colleges & universities, Federally recognized tribal governments, Public & Indian housing authorities, Native American tribal organizations, 501(c)(3) nonprofits, Nonprofits without 501(c)(3) status, Private colleges & universities and 3 more. Additional restrictions may apply; review the full notice.
How do I apply for this opportunity?
Applications are submitted through the official source, not through GrantsJunction. Open the official notice on Grants.gov (opportunity PAR-25-325), and review the full announcement and application package. Organizations applying through Grants.gov generally need an active SAM.gov registration and a Grants.gov account, which can take several weeks to set up.
Related open opportunities
Matched on shared Assistance Listings, agency, categories and eligible applicant types.
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
National Institutes of Health- Award range
- Amount not specified
- Closes
- Oct 8, 2027
- Who can apply
- State governments, County governments, City or township governments and 12 more
Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
National Institutes of Health- Award range
- Amount not specified
- Closes
- Jan 7, 2027
- Who can apply
- State governments, County governments, City or township governments and 12 more
Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed)
National Institutes of Health- Award range
- Amount not specified
- Est. close
- Jan 25, 2027 (est.)
- Who can apply
- State governments, County governments, City or township governments and 12 more
Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
National Institutes of Health- Award range
- Amount not specified
- Est. close
- Jan 25, 2027 (est.)
- Who can apply
- State governments, County governments, City or township governments and 12 more
Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)
National Institutes of Health- Award range
- Amount not specified
- Closes
- Jul 5, 2029
- Who can apply
- State governments, County governments, City or township governments and 12 more
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
National Institutes of Health- Award range
- $50K – $300K
- Closes
- Oct 19, 2027
- Who can apply
- State governments, County governments, City or township governments and 12 more